Management of Chronic Mildly Elevated Liver Enzymes with Normal Imaging

Introduction to Diagnostic Approach

For a patient with mildly elevated liver enzymes and normal imaging, the American Gastroenterological Association recommends performing a comprehensive liver etiology screen, including viral hepatitis serologies, autoimmune markers, iron studies, and immunoglobulins, followed by risk stratification for fibrosis using FIB-4 or NAFLD Fibrosis Score 1, 2

A mixed hepatocellular-cholestatic pattern, as seen in patients with mildly elevated ALT and alkaline phosphatase, suggests either early cholestatic disease, infiltrative liver disease, or metabolic liver disease, despite normal BMI, according to the European Association for the Study of the Liver 1, 2

The standard liver etiology screen should include viral hepatitis serologies, autoimmune markers, iron studies, and immunoglobulins, as recommended by the American Association for the Study of Liver Diseases 2, 4
The FIB-4 score should be calculated using age, ALT, AST, and platelet count to assess the risk of advanced fibrosis, with a score >2.67 indicating high risk, as suggested by the National Institute for Health and Care Excellence 1

The NAFLD Fibrosis Score can be used as an alternative to the FIB-4 score for first-line risk stratification, according to the American Gastroenterological Association 1
If the FIB-4 score is elevated or intermediate, second-line fibrosis assessment should be performed, including serum ELF test or FibroScan/ARFI elastography, as recommended by the European Association for the Study of the Liver 1, 4

Alcohol assessment should be performed, including AUDIT-C screening and full 10-item AUDIT if positive, as recommended by the National Institute on Alcohol Abuse and Alcoholism 1, 4
Primary sclerosing cholangitis (PSC) should be considered in patients with a cholestatic pattern, especially if there is a personal or family history of autoimmune disease or inflammatory bowel disease, according to the American Association for the Study of Liver Diseases 2, 4

Patients should be referred to hepatology/gastroenterology if the extended liver etiology screen is negative and no risk factors for NAFLD are identified, or if the FIB-4 score is >2.67 or there is other evidence of advanced fibrosis, as recommended by the American Gastroenterological Association 1, 2, 4

For patients not meeting referral criteria, liver enzymes should be repeated every 3-6 months initially, and modifiable risk factors should be addressed, including complete alcohol cessation and lifestyle modifications for metabolic syndrome, as suggested by the European Association for the Study of the Liver 1, 5